



BREATHE EASY:

EVALUATION AND
TREATMENT OF

Difficult-to-Control
and Severe
Pediatric Asthma

EARN CME
CREDITS &
ABP MOC
POINTS

DO YOU STRUGGLE MANAGING ASTHMA SYMPTOMS IN YOUR PEDIATRIC PATIENTS?

Long-term management of pediatric asthma can be challenging. During this live activity, our faculty will discuss important clinical pearls and pitfalls related to:

- Assessment of lung function
- Diagnosing asthma in pediatric patients
- Individualizing asthma management plans
- Red flag detection for deteriorating asthma control
- Addressing poor symptom control in pediatric asthma patients
- Symptom management tips for families at home

Upon completion of this activity, learners should be better able to:

- Differentiate between mild to moderate asthma and severe asthma
- Recognize the characteristics of difficult-to-control severe asthma vs treatment-refractory severe asthma and when to refer to a specialist
- Individualize maintenance strategies for patients with pediatric asthma based on current guidelines and disease severity

TARGET AUDIENCE

- Pediatricians



There is no fee to participate in this activity.

Approved for AMA PRA Category 1 Credits™



Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn **1.0 MOC points** in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

October 24, 2018

5:30 PM – 7:30 PM

Arizona Inn

2200 E Elm St,
Tucson, AZ 85719

FACULTY PRESENTER:

Shipra Singh, MD, MPH

Pediatric Pulmonologist

Renown Children's Hospital

Reno, NV

This Live Meeting will be held in cooperation
with the Arizona AAP chapter.

Jointly Provided by **AAACME** & **SPIRE**
AMERICAN ACADEMY OF CME, INC. LEARNING

This activity is supported by an independent educational grant
from Boehringer Ingelheim Pharmaceuticals, Inc.